Edition:
United Kingdom

Foamix Pharmaceuticals Ltd (FOMX.OQ)

FOMX.OQ on NASDAQ Stock Exchange Global Market

3.98USD
14 Dec 2018
Change (% chg)

$-0.02 (-0.50%)
Prev Close
$4.00
Open
$3.98
Day's High
$4.08
Day's Low
$3.96
Volume
100,960
Avg. Vol
169,933
52-wk High
$7.55
52-wk Low
$3.61

Chart for

About

Foamix Pharmaceuticals Ltd. is a clinical-stage pharmaceutical company. The Company is engaged in the development and commercialization of foam-based formulations, using its technology, which includes its foam platforms. It is focused on developing and commercializing its minocycline foam for the treatment of acne, rosacea and... (more)

Overall

Beta: --
Market Cap(Mil.): $241.40
Shares Outstanding(Mil.): 37.43
Dividend: --
Yield (%): --

Financials

  FOMX.OQ Industry Sector
P/E (TTM): -- 69.71 34.39
EPS (TTM): -1.31 -- --
ROI: -49.58 9.01 14.96
ROE: -49.79 10.15 16.52

Foamix's treatment for common skin condition meets late-stage trial goals

Foamix Pharmaceuticals Ltd said on Wednesday its experimental foam treatment for rosacea, a common skin condition that causes acne-like bumps and redness on the face, met the main goals of two late-stage clinical trials.

07 Nov 2018

Foamix's treatment for common skin condition meets late-stage trial goals

Nov 7 Foamix Pharmaceuticals Ltd said on Wednesday its experimental foam treatment for rosacea, a common skin condition that causes acne-like bumps and redness on the face, met the main goals of two late-stage clinical trials.

07 Nov 2018

Foamix acne drug meets main goals in late-stage trial, shares surge

Foamix Pharmaceuticals Ltd said on Tuesday that its lead drug treating moderate-to-severe acne met the main goals of its third late-stage study, sending its shares up 57 percent in extended trading.

11 Sep 2018

UPDATE 1-Foamix acne drug meets main goals in late-stage trial, shares surge

Sept 11 Foamix Pharmaceuticals Ltd said on Tuesday that its lead drug treating moderate-to-severe acne met the main goals of its third late-stage study, sending its shares up 57 percent in extended trading.

11 Sep 2018

Foamix Pharma's acne drug meets main goals in late-stage trial

Sept 11 Foamix Pharmaceuticals Ltd said on Tuesday that its drug treating moderate-to-severe acne met the main goals of its third late-stage study.

11 Sep 2018

Earnings vs. Estimates